Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER‐3 study

Psoriasis, a chronic disease usually requires long‐term disease management.

[1]  M. Lebwohl,et al.  Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. , 2019, Journal of the American Academy of Dermatology.

[2]  M. Lebwohl,et al.  Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections. , 2018, Journal of the American Academy of Dermatology.

[3]  S. Ball,et al.  Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three‐year results from the UNCOVER‐3 study , 2018, Journal of the American Academy of Dermatology.

[4]  L. Iversen,et al.  Efficacy and safety of ixekizumab for the treatment of moderate‐to‐severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER‐3) , 2017, Journal of the American Academy of Dermatology.

[5]  R. Burge,et al.  Rapid improvements in health‐related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER‐2 and UNCOVER‐3 , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[6]  B. Strober,et al.  Short‐ and long‐term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data , 2017, Journal of the American Academy of Dermatology.

[7]  General Principles.  INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE CONTINUOUS MANUFACTURING OF DRUG SUBSTANCES AND DRUG PRODUCTS Q13 , 2017 .

[8]  J. Erickson,et al.  Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. , 2016, The New England journal of medicine.

[9]  M. Lebwohl,et al.  Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials , 2015, The Lancet.

[10]  Sarah L. Gaffen,et al.  The IL-23–IL-17 immune axis: from mechanisms to therapeutic testing , 2014, Nature Reviews Immunology.